Finally, this study found that high‐risk ccRCC patients are highly sensitive to anti‐PD1 immunotherapy and anti‐CTLA4 immunotherapy, and at the same time provide a possible new drug regimen for ccRCC patients and offer a reference for clinical combination drug use. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.